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Background: Prostate-specific antigen (PSA) nadir + 2 ng/mL, also known as the Phoenix definition, is the definition
most commonly used to establish biochemical failure (BF) after external beam radiotherapy for prostate cancer
management. The purpose of this study is to compare BF rates between permanent prostate brachytherapy (PPB)
and radical retropubic prostatectomy (RRP) as a function of PSA nadir plus varying values of X and examine the
associated implications.
Methods and materials: We retrospectively searched for patients who underwent PPB or RRP at our institution
between 1998 and 2004. Only primary patients not receiving androgen-deprivation therapy were included in the
study. Three RRP patients were matched to each PPB patient on the basis of prognostic factors. BF rates were
estimated for PSA nadirs + different values of X.
Results: A total of 1,164 patients were used for analysis: 873 in the RRP group and 291 in the PPB group. Patients were
equally matched by clinical stage, biopsy Gleason sum, primary Gleason grade, and pretherapy PSA value. Median
follow-up was 3.1 years for RRP patients and 3.6 years in the PPB group (P = .01). Using PSA nadir + 0.1 ng/mL for the
definition of BF, the 5-year BF rate was 16.3% for PPB patients and 13.5% for RRP patients (P = .007), whereas at nadir +
2 ng/mL or greater, the BF rates were less than 3% and were indistinguishable between PPB and RRP patients.
Conclusions: In a cohort of well-matched patients who had prostatectomy or brachytherapy, we examined BF as a
function of nadir + X, where X was treated as a continuous variable. As X increases from 0.1 to 2.0 ng/mL, the BF curves
converge, and above 2.0 ng/mL they are essentially indistinguishable. The data presented are of interest as BF
definitions continue to evolve.
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Measuring serum prostate-specific antigen (PSA) is a
recommended means for monitoring patients after radi-
ation therapy [1]. A rising PSA level after treatment is
frequently associated with subsequent clinical failure.
Standardized definitions of biochemical failure (BF)—* Correspondence: davis.brian@mayo.edu
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unless otherwise stated.recurrence of PSA after treatment—have been developed
to evaluate treatment efficacy and to detect clinical failure.
In 1997, the American Society for Therapeutic Radi-
ology and Oncology (ASTRO) defined BF after external
beam radiotherapy (EBRT) as 3 consecutive increases in
PSA after treatment; the date of failure is set (backdated)
at the midpoint between the time of PSA nadir and the
first of the 3 increases [2]. This definition allowed for
comparison of outcomes between treatment methods and
institutions, but it had limitations. The process of backdat-
ing biases the Kaplan-Meier estimates of event-freeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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definition, known as the ASTRO definition, also was not
optimized with respect to predicting clinical progression,
survival, or therapeutic interventions. In 2006, using data
from a multi-institutional database of patients treated with
EBRT, ASTRO revised the definition of BF to be a PSA
value 2 ng/mL greater than the patient’s absolute PSA
nadir (“nadir + 2 ng/mL”) after EBRT [5]. This definition,
known as the Phoenix definition, has been shown to have
improved sensitivity and specificity in predicting subse-
quent clinical failure after radiotherapy as compared with
the ASTRO definition and many other definitions [6-9].
Another advantage of the new definition is that it tends to
limit the number of patients who are designated as having
BF because it does not include those who merely experi-
ence a benign PSA “bounce” [10,11].
The recommended method of defining BF after radical
retropubic prostatectomy (RRP) differs from that after ra-
diation treatment. According to a recommendation by the
American Urological Association Prostate Cancer Guide-
line Panel, the definition of BF after RRP should be an ini-
tial PSA level of 0.2 ng/mL or greater, with a second and
identical confirmatory PSA level [12]. Thus, a PSA level
above some minimal posttherapy level—nadir for radio-
therapy, or undetectable for surgery—has become an im-
portant aspect of evaluating patients after both radiation
and surgical treatment. However, the magnitude of the
PSA value above nadir varies markedly between different
therapies.
The purpose of this study was to compare rates of BF
between well-matched cohorts of patients with prostate
cancer who received two common primary treatment mo-
dalities, permanent prostate brachytherapy (PPB) or RRP,
as a function of varying PSA nadir plus “X”. The results
may aid in the comparison of different BF definitions
across treatment modalities.
Methods and materials
This study was approved by our institutional review
board, and appropriate informed consent was obtained
for review of patients’ medical records. By searching our
prospectively maintained patient databases, we identified
all patients who received PPB and RRP at our institution
between January 1998 and December 2004. All patients
were clinical stage T1c or greater and experienced a de-
crease in PSA or PSA nadir after primary therapy. The
PPB group excluded salvage therapy patients. Prescrip-
tion doses were consistent with those recommended by
the American Brachytherapy Society Guidelines and in-
clude patients treated with I- 125 [13]. The RRP group
excluded all patients who received neoadjuvant therapy
or adjuvant radiation, as well as non–US residents un-
available for regular follow-up. Brachytherapy patients
receiving neoadjuvant cytoreductive hormonal therapywere excluded, whereas high risk patients who received
neoadjuvant and concomitant androgen deprivation but
did not receive adjuvant treatment were included. Three
RRP patients were matched to each PPB patient by a
computerized matching process [14]. Patients were
matched according to Gleason score on biopsy, disease
stage, pretreatment PSA value, age, and year of proced-
ure. Patients were followed up postoperatively with
serum PSA measurement and digital rectal examination
3 to 4 months after treatment and then every 6 months
for the first 5 years and annually thereafter.
Nadir was defined as the lowest PSA value achieved
within 3 years of treatment. Subsequent BF was then de-
fined based on PSA nadir plus “X,” where X varied from
0.1 to 5.0 ng/mL. BF was also considered to have oc-
curred if there was no posttherapy nadir but the defined
PSA increase occurred, if the patient received salvage
treatment, or if androgen-deprivation therapy was imple-
mented for an increasing PSA value after therapy.
We evaluated the 5-year Kaplan-Meier estimate of BF
based on PSA nadir + X. Continuous variables were
summarized as median and range or interquartile range;
categorical variables were reported as number (percent-
age). Associations between continuous variables were
assessed by Spearman’s correlation analysis. Conditional
logistic regression was used to test differences between
matched PPB and RRP patients. A 2-tailed P < .05 was
considered statistically significant. All statistical analyses




A total of 518 patients received PPB and 5,821 patients re-
ceived RRP at our institution during the study period.
After applying inclusion and exclusion criteria, 1,164
matched patients were evaluated for this analysis: 873
RRP patients and 291 PPB patients. Patient characteristics
are summarized in Table 1. Patients were equally matched
by clinical stage (P = .47), biopsy Gleason score (P = .73),
primary Gleason grade (P = .25, data not shown), and pre-
therapy PSA value (P = .95). Median age was similar in the
PPB and RRP groups (69 vs 68 years; P = .11). Median
follow-up was 3.6 years for RRP patients and 3.1 years in
the PPB group (P = .008). Median time to PSA nadir was
3 months after RRP and 2.4 years after PPB (Figure 1).
Brachytherapy implant characteristics for the PPB pa-
tients are summarized in Table 2. A total of 273 patients
underwent prostate brachytherapy monotherapy and 28
underwent combined treatment with external beam radio-
therapy. All twenty patients with Gleason 8 received com-
bined treatment and 8 of 36 patients with Gleason 7 cancer
received combined treatment. Of those patients undergoing
monotherapy, median prostate volume was 39.7 mL, and
Table 1 Patient characteristics
Patient Group
Characteristic PPB (n = 291) RRP (n = 873) P Value
Age, y .11
Median range 69 (41–80) 68 (43–80)
Mean (SD) 67.2 (6.7) 66.6 (6.21)
Clinical stage .47
T1 204 (70.1%) 592 (67.8%)
T2 87 (29.9%) 281 (32.2%)
Biopsy Gleason score .73
6 235 (80.8%) 722 (82.7%)
7 36 (12.4%) 104 (11.9%)
≥8 20 (6.8%) 47 (5.4%)
Pretherapy PSA value, ng/mL .95
Median (IQR) 5.7 (4.1-7.7) 5.8 (4.1-7.6)
Range 0.6-17.5 0.6-23.1
Time from therapy to death or last follow-up, y .008
Median 3.1 3.6
Maximum 6.9 7.5
Systemic progression 4 (1.4%) 4 (0.5%) .10
Biopsy-proven local recurrence 1 (0.3%) 5 (0.6%) .63
Abbreviations: IQR, interquartile range; PPB, permanent prostate brachytherapy; PSA, prostate-specific antigen; RRP, radical retropubic prostatectomy.
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(1.4%) and 4 RRP patients (0.5%) had systemic progres-
sion (P = .10) (Table 1). There were no differences in
local recurrence between the RRP and PPB cohorts:
0.6% vs 0.3% (P = .63).
We compared the rates of BF by PSA nadir plus varying
values of X between the RRP and PPB groups (Figure 2).
At nadir + 0.1 ng/mL, the 5-year BF estimate (SE) for PPB
patients was 16.3% (2.3%) and 13.5% (1.5%) for RRP pa-
tients (P = .007). At nadir + 1.0 ng/mL, 5-year BF was 9.1%Figure 1 Time to Prostate-Specific Antigen (PSA) Nadir. Graph
shows percentage of patients treated with permanent prostate
brachytherapy (PPB; n = 291) and radical retropubic prostatectomy
(RRP; n = 873) reaching PSA nadir by time after treatment.(2.1%) versus 4.9% (1.1%) for the PPB and RRP groups, re-
spectively (P = .09). BF rates were less than 3% at nadir +
2 ng/mL or greater and were indistinguishable between
PPB and RRP patients (P =NS). Using two different defini-
tions of BF based on treatment modality, nadir + 2 ng/mL
or greater for PPB patients and nadir + 0.1 ng/mL or
greater for RRP patients, 5-year BF rates were less than 3%
and 13.5%, respectively.
Discussion
In this study, we applied the most commonly used and ac-
cepted definition of BF in prostate cancer treated with
EBRT to a large group of patients treated with PPB or
RRP. The patients in the two groups were matched by
prognostic factors of Gleason score by biopsy, stage, and
PSA value, and year of procedure. We analyzed and com-
pared rates of BF between patients treated with PPB and
RRP as a function of a varying PSA nadir plus X. The aims
of the study were 1) to examine differences in BF rates in
groups of patients with similar prognostic factors and
similar clinical outcome with respect to systemic progres-
sion, and 2) to provide data to determine if a similar PSA
definition for EBRT, brachytherapy, and surgery is tenable.
To our knowledge, this is the first study to provide such
comparative data and analysis.
Most of the patients in this study had low-risk disease.
Studies have demonstrated similar outcomes in bio-
chemical progression–free survival between men treated
Table 2 Dosimetry characteristics for patients undergoing
monotherapy (I-125) in PPB Group (n = 273)
Characteristic Median (IQR)
Prostate volume, mL 39.7 (31–47)
mCi implanted 42.6 (36.4-48.2)
Prostate D90, Gy 158 (146–174)
Prostate V100,% 94.7 (90.3-97.8)
Rectal V100, mL 0.28 (0.01-1.08)
Abbreviations: D90, isodose enclosing 90% of the prostate; IQR, interquartile
range; PPB, permanent prostate brachytherapy; V100, target volume receiving
100% of the prescribed dose.
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study by Arvold et al. [18] of 5,760 men with low-risk
prostate cancer and 3,079 men with intermediate-risk
prostate cancer found no significant difference in the
risk of prostate cancer–specific mortality between these
groups after RRP or PPB. In our study, there were no
significant differences in systemic progression or biopsy-
proven local recurrence between patients treated with
PPB or RRP.
Although definitions of BF after EBRT have been well
studied, these definitions were not intended to be ap-
plied to patients treated with PPB or RRP; there is no ac-
cepted BF definition that can be applied universally to
patients treated with PPB, RRP, and EBRT. For this rea-
son, it is also of interest to examine how definitions of
BF compare to one another to better assess outcomes
between treatment modalities.
The most commonly used definition of BF after EBRT,
the Phoenix definition, evolved from the previous ASTRO
definition [2]. Several authors have noted limitations with
the ASTRO definition, including not being linked to sur-
vival, clinical progression, or interventions [4,19,20]. The
definition was also very sensitive to follow-up and led toFigure 2 Biochemical Failure (BF) as a Function of Prostate-Specific
Antigen (PSA) Nadir + X. Graph shows Kaplan-Meier estimated 5-year
rate of BF in patients treated with permanent prostate brachytherapy
(PPB; n = 291) and radical retropubic prostatectomy (RRP; n = 873) for
different definitions of PSA nadir + X. The X-axis shows the value of “X”
ng/mL PSA in the equation “PSA nadir + X.”false-positives from benign PSA bounces [10,11]. Several
other PSA definitions were suggested, one of which was
PSA doubling time as a predictor of failure after EBRT
[11,21-23]. In a study of 4,839 patients treated between
1986 and 1995 at 9 academic institutions, Thames et al.
[4] found additional definitions to be superior to the
ASTRO definition in terms of sensitivity, specificity, posi-
tive and negative predictive values, and risk of clinical fail-
ure after BF. These definitions included two increases of
at least 0.5 ng/mL, PSA level at or greater than the current
nadir plus 2 or 3 ng/mL, and PSA level at or greater than
the absolute nadir plus 2 ng/mL. The study found the
Phoenix definition to have better sensitivity (.67) and spe-
cificity (.84) than the ASTRO definition (.61 and .80) for
predicting clinical failure.
Since nadir + 2 ng/mL is the most common definition of
BF after EBRT, it is often used in series of patients treated
with PPB [24,25]. Kuban et al. [26] analyzed 2,693 patients
treated with PPB and found the nadir + 2 ng/mL definition
to provide the best surrogate for failure throughout the
entire follow-up period, similar to patients treated with
EBRT. The nadir + 2 ng/mL definition was more sensitive
and specific than PSA doubling time or a certain number
of PSA increases. Although the intent of our study was
not to propose nadir + 2 ng/mL as a definition of BF for
both PPB and RRP patients, 5-year BF rates in this study
become similar for the two cohorts using a nadir + 2 ng/
mL or greater definition of BF.
After RRP, PSA levels should theoretically become un-
detectable because the source of PSA, the prostate, is
completely excised; therefore, a measureable PSA on
follow-up has traditionally been assumed to indicate BF
after surgery. Stephenson et al. [27] evaluated 10 defini-
tions of BF in 3,125 patients who underwent prostatec-
tomy. The study found that a PSA of at least 0.4 ng/mL
followed by another increase best explained metastatic
progression. In contrast, the Phoenix definition has not
been validated in surgically treated patients and has been
found to delay the diagnosis of BF. In a study of 2,570
patients who underwent RRP, Nielsen et al. [28] found
that the 5-year biochemical control rates for a definition
of nadir + 0.2 ng/mL or more were similar to the 10-year
biochemical control rates using the nadir + 2 ng/mL def-
inition. After reviewing the literature from 1991 to early
2004, the American Urological Association recom-
mended using the nadir + 0.2 ng/mL definition to define
BF after surgery [12].
Analyzing BF as nadir + X allows X to be a continuous
variable. In the present analysis, as PSA continues to in-
crease above nadir, there is less of a difference in BF rates
between RRP and PPB patients. At the ASTRO definition
of nadir + 2 ng/mL, the curves assessing BF between our
matched PPB and RRP cohorts become indistinguishable.
As PSA continues to increase above nadir, the likelihood
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disease progression.
As demonstrated in our study and in the detailed study
by Thames et al. [4], there is a fine line in balancing sensi-
tivity and specificity for choosing a definition for BF. If BF
is defined as a minimal increase in PSA after nadir, sensi-
tivity of BF increases. At a low value of X, a larger patient
population meets the classification for BF, as noted in
Figure 2. By using a minimal increase in PSA after nadir
to define BF, emphasis is placed on treatment and better
recognition of local recurrence. However, specificity in-
creases when using a larger increase in PSA after nadir to
define BF, and the likelihood that these patients had local,
regional, or distant failure is increased. Choosing a defin-
ition that balances specificity and sensitivity was a ques-
tion faced by the ASTRO consensus panel when the
Phoenix definition was established. In our study, we find
similarly indistinguishable outcomes as X continues to in-
crease above nadir + 2 ng/mL.
Although the study contains a large number of patients
it might be expected that a smooth downward trend with
increasing values of X would be observed in Figure 2. This
is most evident in the PPB curve and the increase between
nadir + 0.8 ng/mL and nadir + 0.9 ng/mL. The number of
patients at a given nadir + X level may vary such that
when a failure event occurs, the overall failure rate at a
higher nadir + X may appear greater than for smaller
values of X due to differences in duration of follow up and
patients and number censored at a given nadir + X level.
Nevertheless, the general trend downward as X increases
remains evident and is consistent with prior studies ana-
lyzing PSA failure and EBRT [Thames].
Our study had several limitations. First, our analysis is
subject to many of the limitations common to retro-
spective analyses. It is also a single-institution study,
which may introduce selection bias. Although our co-
horts of PPB and RRP patients were well matched, some
statistical differences were noted in length of maximum
follow-up. Because surgical treatment is relatively more
established in our institution compared with brachyther-
apy, the RRP group had a longer follow-up period at the
time of analysis. However, this is unlikely to have af-
fected our analysis of BF between the two techniques. In
addition, although we observed no significant differences
in systemic progression between the two cohorts, the
small number of total events (n = 8) limits the power for
such comparisons and the ability to link nadir + X with
later clinical events.
Conclusion
In a cohort of well-matched patients who underwent
either RRP or PPB and had similar local recurrence and
systemic failure rates, we examined BF as a function of
PSA nadir + X, where X was treated as a continuousvariable. As X increases from 0.1 to 2.0 ng/mL, the 5-year
Kaplan-Meier BF estimate curves for the two groups con-
verge, and above 2.0 ng/mL they are essentially indistin-
guishable. These data and analysis are of interest in
examining means by which to compare biochemical fail-
ure between differing treatment modalities.
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